The role of statins for primary prevention in non-elderly colorectal cancer patients

Amikar Sehdev, Y. A Chen T Shih, Dezheng Huo, Benjamin Vekhter, Christopher Lyttle, Blase Polite

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: There is conflicting evidence for the role of statins in the primary prevention of colorectal cancer (CRC). We conducted a case control study (N=357,702) in the non-elderly adult US population (age=18-64 years) with the primary objective to examine the association between CRC and statin use. Patients and Methods: MarketScan® databases were used to identify patients with CRC. A case was defined as having an incident diagnosis of CRC. Up to ten individually matched controls (age, sex, region and date of diagnosis) were selected per case. Statin exposure was assessed by prescription tracking in the 12 months prior to the index date. Conditional logistic regression was used to adjust for multiple potential confounders and calculate adjusted odds ratios (AOR). Results: The mean age of participants was 54 years; 52% males and 48% females. In a multivariable model, any statin use was associated with 26% reduced odds of CRC (AOR, 0.74, 95% confidence interval (CI), 0.72-0.77, p<0.001). Age-stratified analyses showed a stronger effect of statins on CRC in participants aged 55 years or younger (AOR, 0.67, 95% CI, 0.63-0.71, p<0.001) than in participants aged above 55 years (AOR, 0.79, 95% CI, 0.76-0.82, p<0.001); the age-by-statin interaction was statistically significant (p<0.001). The dose-response analyses performed with simvastatin only showed a trend towards significance between the duration of simvastatin exposure and odds of developing CRC (p=0.06). Conclusions: Statins appears to reduce the risk of CRC in non-elderly US population. Chemoprevention with statin might be more effective in non-elderly US population.

Original languageEnglish (US)
Pages (from-to)5043-5050
Number of pages8
JournalAnticancer Research
Volume34
Issue number9
StatePublished - Sep 1 2014
Externally publishedYes

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Primary Prevention
Colorectal Neoplasms
Odds Ratio
Simvastatin
Confidence Intervals
Population
Chemoprevention
Prescriptions
Case-Control Studies
Logistic Models
Databases

Keywords

  • Colorectal cancer
  • Database
  • MarketScan®
  • Non-elderly
  • Prevention
  • Statin

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

Sehdev, A., Shih, Y. A. C. T., Huo, D., Vekhter, B., Lyttle, C., & Polite, B. (2014). The role of statins for primary prevention in non-elderly colorectal cancer patients. Anticancer Research, 34(9), 5043-5050.

The role of statins for primary prevention in non-elderly colorectal cancer patients. / Sehdev, Amikar; Shih, Y. A Chen T; Huo, Dezheng; Vekhter, Benjamin; Lyttle, Christopher; Polite, Blase.

In: Anticancer Research, Vol. 34, No. 9, 01.09.2014, p. 5043-5050.

Research output: Contribution to journalArticle

Sehdev, A, Shih, YACT, Huo, D, Vekhter, B, Lyttle, C & Polite, B 2014, 'The role of statins for primary prevention in non-elderly colorectal cancer patients', Anticancer Research, vol. 34, no. 9, pp. 5043-5050.
Sehdev A, Shih YACT, Huo D, Vekhter B, Lyttle C, Polite B. The role of statins for primary prevention in non-elderly colorectal cancer patients. Anticancer Research. 2014 Sep 1;34(9):5043-5050.
Sehdev, Amikar ; Shih, Y. A Chen T ; Huo, Dezheng ; Vekhter, Benjamin ; Lyttle, Christopher ; Polite, Blase. / The role of statins for primary prevention in non-elderly colorectal cancer patients. In: Anticancer Research. 2014 ; Vol. 34, No. 9. pp. 5043-5050.
@article{03b01fec51dd4e30a6ea50a8d1d17442,
title = "The role of statins for primary prevention in non-elderly colorectal cancer patients",
abstract = "Background: There is conflicting evidence for the role of statins in the primary prevention of colorectal cancer (CRC). We conducted a case control study (N=357,702) in the non-elderly adult US population (age=18-64 years) with the primary objective to examine the association between CRC and statin use. Patients and Methods: MarketScan{\circledR} databases were used to identify patients with CRC. A case was defined as having an incident diagnosis of CRC. Up to ten individually matched controls (age, sex, region and date of diagnosis) were selected per case. Statin exposure was assessed by prescription tracking in the 12 months prior to the index date. Conditional logistic regression was used to adjust for multiple potential confounders and calculate adjusted odds ratios (AOR). Results: The mean age of participants was 54 years; 52{\%} males and 48{\%} females. In a multivariable model, any statin use was associated with 26{\%} reduced odds of CRC (AOR, 0.74, 95{\%} confidence interval (CI), 0.72-0.77, p<0.001). Age-stratified analyses showed a stronger effect of statins on CRC in participants aged 55 years or younger (AOR, 0.67, 95{\%} CI, 0.63-0.71, p<0.001) than in participants aged above 55 years (AOR, 0.79, 95{\%} CI, 0.76-0.82, p<0.001); the age-by-statin interaction was statistically significant (p<0.001). The dose-response analyses performed with simvastatin only showed a trend towards significance between the duration of simvastatin exposure and odds of developing CRC (p=0.06). Conclusions: Statins appears to reduce the risk of CRC in non-elderly US population. Chemoprevention with statin might be more effective in non-elderly US population.",
keywords = "Colorectal cancer, Database, MarketScan{\circledR}, Non-elderly, Prevention, Statin",
author = "Amikar Sehdev and Shih, {Y. A Chen T} and Dezheng Huo and Benjamin Vekhter and Christopher Lyttle and Blase Polite",
year = "2014",
month = "9",
day = "1",
language = "English (US)",
volume = "34",
pages = "5043--5050",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "9",

}

TY - JOUR

T1 - The role of statins for primary prevention in non-elderly colorectal cancer patients

AU - Sehdev, Amikar

AU - Shih, Y. A Chen T

AU - Huo, Dezheng

AU - Vekhter, Benjamin

AU - Lyttle, Christopher

AU - Polite, Blase

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Background: There is conflicting evidence for the role of statins in the primary prevention of colorectal cancer (CRC). We conducted a case control study (N=357,702) in the non-elderly adult US population (age=18-64 years) with the primary objective to examine the association between CRC and statin use. Patients and Methods: MarketScan® databases were used to identify patients with CRC. A case was defined as having an incident diagnosis of CRC. Up to ten individually matched controls (age, sex, region and date of diagnosis) were selected per case. Statin exposure was assessed by prescription tracking in the 12 months prior to the index date. Conditional logistic regression was used to adjust for multiple potential confounders and calculate adjusted odds ratios (AOR). Results: The mean age of participants was 54 years; 52% males and 48% females. In a multivariable model, any statin use was associated with 26% reduced odds of CRC (AOR, 0.74, 95% confidence interval (CI), 0.72-0.77, p<0.001). Age-stratified analyses showed a stronger effect of statins on CRC in participants aged 55 years or younger (AOR, 0.67, 95% CI, 0.63-0.71, p<0.001) than in participants aged above 55 years (AOR, 0.79, 95% CI, 0.76-0.82, p<0.001); the age-by-statin interaction was statistically significant (p<0.001). The dose-response analyses performed with simvastatin only showed a trend towards significance between the duration of simvastatin exposure and odds of developing CRC (p=0.06). Conclusions: Statins appears to reduce the risk of CRC in non-elderly US population. Chemoprevention with statin might be more effective in non-elderly US population.

AB - Background: There is conflicting evidence for the role of statins in the primary prevention of colorectal cancer (CRC). We conducted a case control study (N=357,702) in the non-elderly adult US population (age=18-64 years) with the primary objective to examine the association between CRC and statin use. Patients and Methods: MarketScan® databases were used to identify patients with CRC. A case was defined as having an incident diagnosis of CRC. Up to ten individually matched controls (age, sex, region and date of diagnosis) were selected per case. Statin exposure was assessed by prescription tracking in the 12 months prior to the index date. Conditional logistic regression was used to adjust for multiple potential confounders and calculate adjusted odds ratios (AOR). Results: The mean age of participants was 54 years; 52% males and 48% females. In a multivariable model, any statin use was associated with 26% reduced odds of CRC (AOR, 0.74, 95% confidence interval (CI), 0.72-0.77, p<0.001). Age-stratified analyses showed a stronger effect of statins on CRC in participants aged 55 years or younger (AOR, 0.67, 95% CI, 0.63-0.71, p<0.001) than in participants aged above 55 years (AOR, 0.79, 95% CI, 0.76-0.82, p<0.001); the age-by-statin interaction was statistically significant (p<0.001). The dose-response analyses performed with simvastatin only showed a trend towards significance between the duration of simvastatin exposure and odds of developing CRC (p=0.06). Conclusions: Statins appears to reduce the risk of CRC in non-elderly US population. Chemoprevention with statin might be more effective in non-elderly US population.

KW - Colorectal cancer

KW - Database

KW - MarketScan®

KW - Non-elderly

KW - Prevention

KW - Statin

UR - http://www.scopus.com/inward/record.url?scp=84908667403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908667403&partnerID=8YFLogxK

M3 - Article

C2 - 25202089

AN - SCOPUS:84908667403

VL - 34

SP - 5043

EP - 5050

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 9

ER -